ALK-Positive Non-Small Cell Lung CancerSymptoms, Doctors, Treatments, Advances & More
Learn About ALK-Positive Non-Small Cell Lung Cancer
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Interventional Radiology In San Jose
Heather Wakelee is an Oncologist practicing medicine in San Jose, California. Dr. Wakelee is rated as an Elite provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Thymectomy, and Tissue Biopsy.
Northwell Health Physician Partners At Downtown Flushing
Paul Lee is a Thoracic Surgeon practicing medicine in Flushing, New York. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, Thymectomy, and Advanced Bronchoscopy. Dr. Lee is board certified in American Board Of Thoracic Surgery and American Board Of Surgery. Dr. Lee is currently accepting new patients.
Fred & Pamela Buffett Cancer Center - Nebraska Medical Center
Rudy Lackner is a Thoracic Surgeon practicing medicine in Omaha, Nebraska. Dr. Lackner is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Squamous Cell Lung Carcinoma, Endoscopy, and Thymectomy. Dr. Lackner is currently accepting new patients.
Summary: This phase I trial is studying the safety, side effects, and best dose of gilteritinib in treating patients with stage IV ALK positive non-small cell lung cancer (NSCLC) who have progressed on other treatments. While there are many approved targeted drugs for ALK NSCLC, resistance to these drugs frequently occur. Giltertinib is a drug that is already FDA approved for the treatment of a specific ty...
Summary: This is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initially treated with lorlatinib for 12 weeks.